Alterity Therapeutics Limited – Sponsored ADR (ATHE) – What Are Investment Firms Thinking About This Stock?

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) has received a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $10.00.

Several equities research analysts have commented on ATHE shares. UBS Group set a $12.00 price objective on Alterity Therapeutics in a research report on Tuesday, August 11th. Weiss Ratings raised shares of Alterity Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 12th. Craig Hallum set a $2.00 price objective on shares of Alterity Therapeutics in a research note on Tuesday, August 11th. Lake Street Capital assumed coverage on shares of Alterity Therapeutics in a report on Tuesday, September 15th. They set a “buy” rating and a $10.00 target price for the company. Finally, JonesTrading assumed coverage on shares of Alterity Therapeutics in a research note on Tuesday, June 30th. They issued a “buy” rating and a $16.00 target price for the company.

Alterity Therapeutics Stock Performance

Shares of ATHE opened at $2.09 on Friday. Alterity Therapeutics has a 52 week low of $2.04 and a 52 week high of $5.89. The stock’s 50-day moving average price is $3.74 and its 200-day moving average price is $4.27.

Alterity Therapeutics (NASDAQ:ATHE) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.28) earnings per share for the quarter. The company had revenue of $0.31 million during the quarter. Research analysts predict that Alterity Therapeutics will post -0.12 EPS for the current fiscal year.

Institutional Trading of Alterity Therapeutics

A hedge fund recently raised its position in Alterity Therapeutics stock. Greenleaf Trust raised its position in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) by 93.8% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 62,000 shares of the company’s stock after buying an additional 30,000 shares during the period. Greenleaf Trust owned about 0.70% of Alterity Therapeutics worth $333,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited (NASDAQ: ATHE) is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research centers on protein misfolding and aggregation, biological processes associated with conditions such as multiple system atrophy (MSA) and Parkinson’s disease.

Alterity’s lead drug candidate is ATH434, an orally administered small molecule designed to inhibit the aggregation of alpha-synuclein, a protein implicated in several neurodegenerative disorders.